A perspective: the integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for phase II immunotherapy clinical trials

Basit Öğe Kaydı
dc.contributor.authorKus, T.
dc.contributor.authorCicin, I.
dc.date.accessioned2024-05-19T14:33:46Z
dc.date.available2024-05-19T14:33:46Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractA consensus guideline, iRECIST, was developed by the Response Evaluation Criteria in Solid Tumours (RECIST) working group for the use of the modified RECIST version 1.1 in cancer immunotherapy trials. iRECIST was designed to separate pseudoprogression from real progression. However, this is not the only ambiguous situation. In clinical immunotherapy trials, stable disease may reflect three tumor responses, including real stable disease, progressive disease and responsive disease. The prediction of a “true complete/partial response” is also important. Much data has accumulated showing that ctDNA can guide decisions at this point; thus, integrating ctDNA into the RECIST 1.1 criteria may help to distinguish a true tumor response type earlier in patients treated with immunotherapy; however, prospectively designed validation studies are needed. © 2024 Expert Publishing Medicine Ltd.en_US
dc.identifier.doi10.2217/imt-2023-0184
dc.identifier.endpage329en_US
dc.identifier.issn1750-743X
dc.identifier.issue5en_US
dc.identifier.pmid38197142en_US
dc.identifier.scopus2-s2.0-85184658500en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage319en_US
dc.identifier.urihttps://doi.org/10.2217/imt-2023-0184
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4330
dc.identifier.volume16en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherNewlands Press Ltden_US
dc.relation.ispartofImmunotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectCtdnaen_US
dc.subjectİmmunotherapyen_US
dc.subjectİrecısten_US
dc.subjectPhase 2en_US
dc.subjectRecıst 1.1en_US
dc.subjectTumor Assesmenten_US
dc.titleA perspective: the integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for phase II immunotherapy clinical trialsen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu